SpringerLink
Log in

Lung cancer

Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC

  • Research Highlight
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Peter Sidaway

Authors
  1. Peter Sidaway
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00915-w

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41571-024-00915-w

  • Springer Nature Limited

Search

Navigation